This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more
Key findings regarding androgen-targeted therapy resistance: Androinz.Reverse_Treatment.1.var
Based on recent research into prostate cancer treatment, remains a key target, but therapy resistance (specifically, castration-resistant prostate cancer, or CRPC) is a major challenge. Research highlights that, while standard treatments like enzalutamide or abiraterone are used, tumor resistance often emerges through the adaptation of AR variants (e.g., AR-V7 , ARv567es ). This is for informational purposes only
These truncated variants (like ARv567es) lack the ligand-binding domain but remain constitutively active, driving resistance to castration and newer antiandrogens. While potent AR inhibitors are used, they can
While potent AR inhibitors are used, they can force tumors to de-differentiate into AR-negative disease. For more specific information, pleaseg., ARv567es or AR-V7) The effect of specific drugs (e.g., enzalutamide) The role of ROR-γ in treatment resistance To narrow this down, Clinical trial outcomes for resistance? A summary of new therapeutic targets being researched?
Resistance is also mediated by non-canonical pathways, such as ROR-γ (retinoic acid receptor-related orphan receptor γ), which acts as a driver of AR expression in CRPC.